Literature DB >> 9593594

Proconvulsant effects of neurosteroids pregnenolone sulfate and dehydroepiandrosterone sulfate in mice.

D S Reddy1, S K Kulkarni.   

Abstract

We have investigated the effects of chronic treatment with the neurosteroids, pregnenolone sulfate and dehydroepiandrosterone sulfate, on the potential neurotoxicity in pentylenetetrazol seizure sensitivity test in mice. Four weeks of subcutaneous treatment with pregnenolone sulfate and dehydroepiandrosterone sulfate, at a dose of 10 mg kg(-1) day(-1), significantly shifted the pentylenetetrazol dose-percent convulsions and latency curves to the left, and markedly decreased the ED50 of pentylenetetrazol for tonic convulsions, indicating the increased sensitivity of mice to seizures. Chronic neurosteroid treatment significantly decreased the body weight of the animals. However, acute treatment of neurosteroids did not modify the seizure reactivity of mice to pentylenetetrazol. Furthermore, the dehydroepiandrosterone sulfate (10 mg kg(-1), s.c.)-induced proconvulsant effect was significantly prevented by chronic pretreatment with progesterone (5 mg kg(-1), s.c.), a precursor for GABA(A) receptor active neurosteroid, allopregnanolone, and dizocilpine (0.1 mg kg(-1), i.p.), a non-competitive NMDA receptor antagonist. These results suggest that long-term administration of neurosteroids pregnenolone sulfate or dehydroepiandrosterone sulfate produces proconvulsant effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593594     DOI: 10.1016/s0014-2999(98)00034-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

Review 1.  Neurosteroids: endogenous role in the human brain and therapeutic potentials.

Authors:  Doodipala Samba Reddy
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 2.  Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2017-11-15       Impact factor: 4.030

Review 3.  Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability.

Authors:  Chase Matthew Carver; Doodipala Samba Reddy
Journal:  Psychopharmacology (Berl)       Date:  2013-09-27       Impact factor: 4.530

4.  Allopregnanolone potentiates the glutamate-mediated seizures induced by 4-aminopyridine in rat hippocampus in vivo.

Authors:  Patricia Salazar; Ricardo Tapia
Journal:  Neurochem Res       Date:  2011-11-12       Impact factor: 3.996

Review 5.  Therapeutic potential of pregnenolone and pregnenolone methyl ether on depressive and CDKL5 deficiency disorders: Focus on microtubule targeting.

Authors:  Isabella Barbiero; Massimiliano Bianchi; Charlotte Kilstrup-Nielsen
Journal:  J Neuroendocrinol       Date:  2021-09-08       Impact factor: 3.870

Review 6.  The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment.

Authors:  Constance Guille; Susan Spencer; Idil Cavus; C Neill Epperson
Journal:  Epilepsy Behav       Date:  2008-03-17       Impact factor: 2.937

Review 7.  The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Epilepsy Res       Date:  2009-04-29       Impact factor: 3.045

Review 8.  Neurosteroid regulation of GABAA receptors: A role in catamenial epilepsy.

Authors:  Suchitra Joshi; Jaideep Kapur
Journal:  Brain Res       Date:  2018-02-23       Impact factor: 3.252

9.  Characterization of the convulsant action of pregnenolone sulfate.

Authors:  John Williamson; Zakaria Mtchedlishvili; Jaideep Kapur
Journal:  Neuropharmacology       Date:  2004-05       Impact factor: 5.250

10.  Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Front Endocrinol (Lausanne)       Date:  2011-10-05       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.